

Alpha Stem Cell Clinics Trials



The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials.




Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials


Alpha Clinic	Alpha Clinic Contact	Trial Sponsor	Disease Indication	Clinical Trial Name	Status of Enrollment ▲	Learn More
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)	Recruiting	
City of Hope	Karen Reckamp, MD (626) 256-4673 x89200 kreckamp@coh.org	Adaptimmune	Cancer - Lung	Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC	Recruiting	
City of Hope	Mihaela Cristea, MD (626) 256-4673 x89200 mcristea@coh.org	Adaptimmune	Cancer - Ovarian	A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.	Recruiting	
City of Hope	Nadia Ewing, MD (626) 256-4673 x89200 newing@coh.org	Sangamo Therapeutics	Hemophilia A	Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A	Recruiting	
City of Hope	Hormoz Babaei Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Adaptimmune	Cancer - Myeloma	NY-ESO-1 ^{C259T} Alone and in Combination With Pembrolizumab for Multiple Myeloma	Recruiting	
City of Hope	Nadia Ewing, MD (626) 256-4673 x89200 newing@coh.org	Sangamo Therapeutics	Hemophilia B	Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B	Recruiting	
City of Hope	Rie Miyahira 626-256-4673 ext 80032 rmiyahira@coh.org	Angiocrine Bioscience	Cancer - Leukemia	A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation	Recruiting	

City of Hope	Cara Nolan 626-256-4673 ext 32341 cnolan@coh.org	Juno Therapeutics	Cancer - Lymphoma	Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)	Recruiting	
City of Hope	Elizabeth Budde, MD 626-218-2405	Kite Pharma	Cancer - Lymphoma	A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma	Recruiting	
City of Hope	Hormoz Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Kite Pharma	Cancer - Lymphoma	A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6)	Recruiting	
City of Hope	Hormoz Babaei Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Celgene	Cancer - Lymphoma	An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM)	Recruiting	
City of Hope	Teresa Kim 626-218-0263 teresakim@coh.org	City of Hope	Sickle Cell Disease	A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant	Recruiting	
City of Hope	Hormoz Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Kite Pharma	Cancer - Lymphoma	A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1)	Recruiting	
City of Hope	Cara Nolan 626-218-3241 canolan@coh.org	Juno Therapeutics	Cancer - Lymphoma	An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)	Recruiting	
City of Hope	Erminia Massarelli 626-218-9200 emassarelli@coh.org	Tessa Therapeutics	Cancer - Nasopharyngeal Carcinoma	A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea	Recruiting	

City of Hope & UCLA	City of Hope: Amrita Krishnan, MD (626) 256-4673 ext 62405 AKrishnan@coh.org UCLA: Maricella Gonzalez 310-557-3729 mmgonzalez@mednet.ucla.edu	City of Hope	HIV/AIDS	Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients	Recruiting	
City of Hope	Lucy Ghoda 626-218-3605 lghoda@coh.org	City of Hope	Neurodegenerative Disorder	Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies	Recruiting	
City of Hope	Jana Portnow, MD (626) 256-4673 ext 62909 jportnow@coh.org	City of Hope	Cancer - Brain	Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas	Recruiting	
City of Hope	Behnam Badie, MD (626) 256-4673 ext 60098 bbadie@coh.org	City of Hope	Cancer - Brain	Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma	Recruiting	
City of Hope	L. Elizabeth Budde, MD, PhD (626) 256-4673 ebudde@coh.org	City of Hope	Cancer - Leukemia	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	UC Davis	Cancer - Tongue Dysphagia	Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Capricor Therapeutics	Muscle - Duchenne Muscular Dystrophy	A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	Nohla Therapeutics	Cancer – Leukemia	Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	UC Davis	Cancer - Lymphoma (HIV-Related)	Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant	Recruiting	
UC Davis	Jane McCluskey 916-703-9302 jmcccluskey@ucdavis.edu	UC Davis	Eye - Retinopathy	Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy	Recruiting	

UCI & UC Davis	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu UC Davis: Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Humacyte	Kidney Failure	Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis	Recruiting	
UCI	UCI Stem Cell Clinic 9498243990 stemcell@uci.edu	Longeveron	Aging frailty	Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty	Recruiting	
UCI	UCI Stem Cell Clinic 9498243990 stemcell@uci.edu	Aivita Biomedical	Cancer - Brain	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma	Recruiting	
UCI	UCI Stem Cell Clinic 9498243990 stemcell@uci.edu	Stratetech	Burn wounds	StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements	Recruiting	
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	BrainStorm Cell Therapeutics	Amyotrophic Lateral Sclerosis (ALS)	Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients	Recruiting	
UCLA	Fabrizia Urbinati, PhD (310) 794-1884 furbinati@ucla.edu	UCLA	Sickle Cell Disease	Stem Cell Gene Therapy for Sickle Cell Disease	Recruiting	
UCLA	Caroline Kuo, MD 310-794-1940 ckuo@mednet.ucla.edu	UCLA	X-linked Chronic Granulomatous Disease	Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease	Recruiting	
UCLA	Siwen Hu-Lieskovan, M.D. 310-206-8477 ext 28099 shu-lieskovan@mednet.ucla.edu	UCLA	Cancer	Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Viacyte	Diabetes - Type 1	Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Viacyte	Diabetes - Type 1	A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Mesoblast	Heart Failure	The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure	Recruiting	

UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Viacyste	Diabetes - Type 1	A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Persimmune, Inc.	Cancer - Blood	Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens	Recruiting	
UCSD	Barbara Parker, MD 858-822-6135 baparker@ucsd.edu Rebecca Shatsky, MD 858-657-7000 rshatsky@ucsd.edu	UCSD	Cancer - Breast	Study of Cirtumzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer	Recruiting	
UCSD	Teresa Rzesiewicz 844-317-7836 alphastemcellclinic@ucsd.edu	Discgenics	Degenerative Disc Disease	Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration	Recruiting	
UCSD & City of Hope	(844) 317-7836 alphastemcellclinic@ucsd.edu	UCSD	Cancer - Leukemia	A Study of the Cirtumzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Persimmune, Inc.	Cancer - Blood	Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)	Recruiting	
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Neuralstem	Spinal Cord Injury	Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI	Recruiting	
UCSF	Cyrus Bascon 510-428-3885 ext 5396 CBascon@mailcho.org	bluebird bio	Sickle Cell Disease	A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease	Recruiting	
UCSF & UCLA	Marci Moriarty, BSN, RN 510-428-3885 ext 5396 mmoriarty@mailcho.org Bruck Habtemariam 310-794-0242 bhabtemariam@mednetucla.edu	Sangamo Therapeutics	Blood Disorder - Beta-Thalassemia	A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)	Recruiting	
UCSF	Romobia Hutchinson 415-476-9326 romobia.hutchinson@ucsf.edu	UCSF	Blood Disorder - Alpha Thalassemia Major	In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)		

City of Hope	Warren Chow, MD (626) 256-4673 x89200 wchow@coh.org	Adaptimmune	Cancer - Sarcoma	A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma	Active, not recruiting	
City of Hope	Hormoz Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Kite Pharma	Cancer - Lymphoma	A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)	Active, not recruiting	
City of Hope	Jana Portnow, MD (626) 256-4673 ext 62909 jportnow@coh.org	City of Hope	Cancer - Brain	Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas	Active, not recruiting	
City of Hope	Amrita Krishnan, MD (626) 256-4673 ext 62405 AKrishnan@coh.org	City of Hope	Cancer - Lymphoma (AIDS-Related)	Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma	Active, not recruiting	

1 2 next > last »

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials.

Find Out More:

About Alpha Stem Cell Clinics

Alpha Clinics News

Source URL: https://www.cirm.ca.gov/patients/alpha-clinics-network/alpha-clinics-trials?order=field_enrollment_status&sort=asc